Dupilumab Drug Aliquot | Anti-IL23/IL4 | Therapeutic Antibody

Aliquoted from the original reference drug | Now available for research use

Aliquots of the reference drug Dupilumab are now available as research consumables.

Dupilumab drug aliquots can be used for in vitro or in vivo experiments. For biosimilar development, different batches of Dupilumab drug can be ordered at the same time. Several other reference drugs are also available.

The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.

Not looking for Dupixent Dupilumab Reference Drug?

Search our therapeutic molecules product database

Quick Ordering

Find and order your therapeutic molecules through smart filters

Multiple Batches

Up to 10 batches of original drugs for examining batch-to-batch variations

Reduce Costs

Up to 80% less compared to the original pharmaceutical price

Worldwide Shipping

Shipment within days worldwide according to GDP-standards

Precise Quantity​​

Up to 80% less compared to the original pharmaceutical price

Drug nameDupixent   
INNDupilumab
API typeDupilumab is a fully human monoclonal antibody against interleukin (IL)-4 receptor alpha that inhibits IL-4/IL-13 signalling, produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.
Pharmacotherapeutic groupOther dermatological preparations, agents for dermatitis, excluding corticosteroids
ATC codeD11AH05
Target of antibodyIL-13, IL-4
General functionDupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and
adolescents 12 years and older who are candidates for systemic therapy. Dupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for
severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised
fraction of exhaled nitric oxide (FeNO).
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Dupilumab is a recombinant human IgG4 monoclonal antibody that inhibits interleukin-4 and interleukin-13 signaling. Dupilumab inhibits IL-4 signaling via the Type I receptor (IL-4Rα/γc), and both IL-4 and IL-13 signaling through the Type II receptor (IL-4Rα/IL-13Rα). IL-4 and IL-13 are major drivers of human type 2 inflammatory disease, such as atopic dermatitis, asthma, and CRSwNP. Blocking the IL-4/IL-13 pathway with dupilumab in patients decreases many of the mediators of type 2 inflammation.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)In atopic dermatitis clinical trials, treatment with dupilumab was associated with decreases from baseline in concentrations of type 2 immunity biomarkers, such as thymus and activation-regulated chemokine (TARC/CCL17), total serum IgE and allergen-specific IgE in serum. A reduction of lactate dehydrogenase (LDH), a biomarker associated with AD disease activity and severity, was observed with dupilumab treatment in adults and adolescents with atopic dermatitis. In asthma clinical trials, dupilumab treatment markedly decreased FeNO and circulating
concentrations of eotaxin-3, total IgE, allergen specific IgE, TARC, and periostin in asthma subjects.
relative to placebo
Original license holder
Marketing authorisation numbersEU/1/17/1229/002
Marketing authorisation holdersanofi-aventis groupe 54, rue La Boétie 75008 Paris France
Name of the manufacturer of the biological active substanceREGENERON PHARMACEUTICALS INC. 81 Columbia Turnpike RENSSELAER NEW YORK 12144 UNITED STATES; Regeneron Ireland Designated Activity Company (DAC) Ballycummin Raheen Business Park Limerick Ireland; Genzyme Flanders BVBA Cipalstraat 8, B-2440 Geel Belgium
Name and address of the manufacturer(s) responsible for batch releaseSANOFI WINTHROP INDUSTRIE 1051 Boulevard Industriel, 76580 LE TRAIT, FRANCE; Sanofi-Aventis Deutschland GmbH Brüningstrasse 50 Industriepark Hoechst 65926 FRANKFURT AM MAIN GERMANY
Max shelf life3 years
Storage conditions2°C - 8°C
List of excipientsarginine hydrochloride - histidine - polysorbate 80 (E433) - sodium acetate trihydrate - glacial acetic acid (E260) - sucrose - water for injections

Evidentic – fast, accurate, secure

Our products are empowering researchers worldwide​

Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.